title: [Use of tactivin and imunofan for the treatment of patients with endometrial carcinoma].
abstract: Immunofan and tactivin, employed as a means of immunological correction in the complex treatment of adenocarcinoma, decrease the onset frequency of radiation-induced complications and exhibit a pronounced immunocorrector effect. This was indicated by increasing level of lymphocytes (including CD3+, CD4+, CD8+, and CD19+), helper coefficient (CD4+/CD8+), and phagocyte activity of neutrophils, as well as by the tendency to normalization of the HCT-test results. Immunofan somewhat exceeds tactivin in the efficacy of endometrium adenocarcinoma treatment.
authors.affiliation: Regional Oncologic Dispensary, ul. 15 Let Oktyabrya 37, Tver, 170008 Russia.
authors.forename: M G
authors.initials: MG
authors.lastname: Venediktova
mesh_terms: D000230:Adenocarcinoma / Q000276:immunology* / Q000532:radiotherapy; D000276:Adjuvants, Immunologic / Q000009:adverse effects / Q000627:therapeutic use*; D015703:Antigens, CD / Q000097:blood; D016516:CD4-CD8 Ratio; D016889:Endometrial Neoplasms / Q000276:immunology* / Q000532:radiotherapy; D005260:Female; D006801:Humans; D006968:Hypersensitivity, Delayed; D008875:Middle Aged; D009504:Neutrophils / Q000276:immunology; D009842:Oligopeptides / Q000009:adverse effects / Q000627:therapeutic use*; D010455:Peptides / Q000009:adverse effects / Q000627:therapeutic use*; D010587:Phagocytosis / Q000187:drug effects; D011788:Quality of Life; D013949:Thymus Extracts / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000276:Adjuvants, Immunologic; D015703:Antigens, CD; D009842:Oligopeptides; D010455:Peptides; D013949:Thymus Extracts; C080035:thymohexin; C036191:T-activin
vernacular_title: Primenenie taktivina i immunofana pri lechenii bol'nykh adenokartsinomoĭ éndometriia.